Yung Hong Biotech Announces Board Approval of 115 Q2 Individual Financial Report

1. Date reported to or resolved by the Board of Directors: 115/07/27 2. Audit Committee approval date: 115/07/23 3. Reporting period for financial report or self-compiled annual financial information Start and end dates (YYY/MM/DD ~ YYY/MM/DD): 115/01/01 ~ 115/06/30 4. Cumulative operating revenue from January 1 to current period (in thousand NT$): 744,081 5. Cumulative operating gross profit (loss) from January 1 to current period (in thousand NT$): 278,151 6. Cumulative operating income (loss) from January 1 to current period (in thousand NT$): 103,961 7. Cumulative pre-tax net profit (loss) from January 1 to current period (in thousand NT$): 104,381 8. Cumulative net profit (loss) for the period from January 1 to current period (in thousand NT$): 83,142 9. Cumulative net profit (loss) attributable to owners of parent from January 1 to current period (in thousand NT$): 83,142 10. Cumulative basic earnings per share (loss) from January 1 to current period (in NT$): 1.14 11. Total assets at end of period (in thousand NT$): 1,775,117 12. Total liabilities at end of period (in thousand NT$): 449,670 13. Equity attributable to owners of parent at end of period (in thousand NT$): 1,325,447 14. Other matters to be disclosed: None